Alexis LeVee, Clinical Instructor at UCLA Health, shared a post on LinkedIn:
“Excited to share our ASCO Educational Book article on updates in management of stage 2-3 TNBC.
In this article, we review:
- Current standard of care for stage 2-3 TNBC
- Novel investigational therapies and combination strategies, including ADCs, anti-VEGF therapies, dual ICI, and locoregional therapies
- Emerging biomarker strategies such as TILs, immune signatures, and ctDNA
- Ongoing clinical trials in stage 2-3 TNBC.”
Title: Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer
Authors: Alexis LeVee, Maeve A. Hennessy, Dame Idossa, Roberto A. Leon-Ferre, Rita Nanda, Heather McArthur
Other Articles Featuring Alexis LeVee On OncoDaily.